Cargando…

Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment

BACKGROUND: To achieve optimal outcomes, an individual approach is needed in the treatment and care of patients. The potential value of tumor mutational burden (TMB) status and/or programmed cell death ligand 1 (PD-L1) expression as biomarkers to predict which patients are most likely to respond to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krieger, Tina, Pearson, Isobel, Bell, Judith, Doherty, Jim, Robbins, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990470/ https://www.ncbi.nlm.nih.gov/pubmed/32000815 http://dx.doi.org/10.1186/s13000-020-0927-9

Ejemplares similares

Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer
por: Li, Wen-Qian, et al.
Publicado: (2020)

Clinical experience of immune checkpoint inhibitor for a metastatic jejunal cancer patient with a high tumor mutational burden and low expression of programmed death-ligand 1
por: Kim, Seo Ree, et al.
Publicado: (2020)

Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer
por: Leapman, Michael S., et al.
Publicado: (2020)

Status of programmed death-ligand 1 expression in sarcomas
por: Park, Hyung Kyu, et al.
Publicado: (2018)

The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer
por: Jang, Jae Yeon, et al.
Publicado: (2023)

Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status
por: Karimi, Shirin, et al.
Publicado: (2021)

Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
por: Park, Jang-June, et al.
Publicado: (2021)

Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy
por: Chatrath, Ajay, et al.
Publicado: (2021)

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
por: Moeckel, Camille, et al.
Publicado: (2023)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model
por: Teng, Chiao-Fang, et al.
Publicado: (2020)

DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
por: Hsiehchen, David, et al.
Publicado: (2020)

Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis
por: Kim, Jinchul, et al.
Publicado: (2018)

Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity
por: Tampe, Désirée, et al.
Publicado: (2022)

Garcinia mangostana L. Pericarp Extract and Its Active Compound α-Mangostin as Potential Inhibitors of Immune Checkpoint Programmed Death Ligand-1
por: Naing, Sandar, et al.
Publicado: (2023)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018)

Correction notice to “Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model”
por: Teng, Chiao-Fang, et al.
Publicado: (2021)

Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer
por: Wang, Shiqiang, et al.
Publicado: (2020)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition
por: Hakroush, Samy, et al.
Publicado: (2021)

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
por: Wang, Victoria E., et al.
Publicado: (2017)

Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Kim, Jong Yeob, et al.
Publicado: (2019)

Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis
por: Wan, Linghong, et al.
Publicado: (2020)

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
por: Valero, Cristina, et al.
Publicado: (2021)

Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
por: Hsiehchen, David, et al.
Publicado: (2021)

Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Tibaldi, Carmelo, et al.
Publicado: (2017)

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
por: Muszak, Damian, et al.
Publicado: (2021)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control
por: Heckl, Steffen M., et al.
Publicado: (2021)

Expression of Programmed Cell Death Ligand-1 and Mismatch Repair Status in Endometrial Carcinomas
por: Rajendran, Madhubala, et al.
Publicado: (2023)

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis
por: Chang, Katherine, et al.
Publicado: (2014)

Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report
por: Wu, Mingrui, et al.
Publicado: (2022)

Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors
por: Shinojima, Naoki, et al.
Publicado: (2023)

Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer
por: Sun, Li‐Yue, et al.
Publicado: (2021)

The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC
por: Yang, Haitao, et al.
Publicado: (2017)

Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country
por: How, Soon Hin, et al.
Publicado: (2022)

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
por: Li, Liu, et al.
Publicado: (2023)

The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors: A meta-analysis
por: Zhang, Jingyi, et al.
Publicado: (2021)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vk72fnumdmr9iabf0eg85m7m03